Novo Nordisk A/S Class B Intangible Assets

Novo Nordisk A/S Class B's intangible assets stands at $92B as of September 2026. That compares with $110B in the prior-year period — down 13.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Novo Nordisk A/S Class B reported $92B in intangible assets versus $110B a year earlier — a 13.4% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $110B in the prior-year period — down 13.4% year over year. Sustained growth in intangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Novo Nordisk A/S Class B's intangible assets evolved across reporting periods, while the comparison chart places NONOF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, intangible assets is commonly used to spot outliers. Novo Nordisk A/S Class B's reading of $92B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.